CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine careWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D009205 Myocarditis NIH 0.38

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0012819 Myocarditis HPO 0.38

There is one clinical trial.

Clinical Trials

1 Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19

COVID-19 outbreak is often lethal. Mortality has been associated with several cardio-vascular risk factors such as diabetes, obesity, hypertension and tobacco use. Other clinico-biological features predictive of mortality or transfer to Intensive Care Unit are also needed. Cases of myocarditis have also been reported with COVID-19. Cardio-vascular events have possibly been highly underestimated. The study proposes to systematically collect cardio-vascular data to study the incidence of myocarditis and coronaropathy events during COVID-19 infection.We will also assess predictive factors for transfer in Intensive Care Unit or death.

NCT04320017 COVID-19 Myocardial Injury Myocarditis Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
MeSH:Myocarditis
HPO:Myocarditis

Primary Outcomes

Description: Viral myocarditis or myocardial infarction or stenosis detected with ST segment elevation or depression associated with troponine elevation and transthoracic echocardiography

Measure: Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay

Time: ECG and concomitant troponine at day 1 after admission at day 1, day 3 day 6 the first week after admission, and then at day 14 and before the patient is discharged (up to 20 days)

Secondary Outcomes

Description: Cardio-vascular events including but not limited to: myocardial infarction or stenosis, stroke, pulmonary embolism, deep vein thrombosis, ventricular dysfunctio, conduction disorders and sudden death

Measure: Description of cardiovascular outcomes in the cohort

Time: During hospital admission (up to 20 days)

Description: Biological biomarkers including but not limited to: baseline troponine T, D-dimers, NT-proBNP, creatinine phosphokinase, creatininemia, ionogram, renine-angiotensin aldosterone system profiling, glycemia (fasting), HbA1c, steroid profiling, lipid profiling

Measure: Prognosis role of baseline cardio-vascular caracteristics on patients survival

Time: 1st day of admission

Measure: Prediction of cardio-vascular events with baseline characteristics

Time: Baseline on first day of admission

Description: Biological markers including but not limited to: C reactive protein, procalcitonine, fibrinogen, interleukin-6

Measure: Characterization of inflammation on cardio-vascular outcomes

Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)

Description: clinical features at baseline: WHO performans status comorbidities and treatments Biological markers including but not limited to: full blood count, C reactive protein, procalcitonine, fibrinogen, interleukin-6, troponin and brain natriuretic peptide

Measure: Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival

Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)

Related HPO nodes (Using clinical trials)

HP:0012819: Myocarditis
Genes 4
SLC2A10 GPX4 PPA2 GPX4
Protein Mutations 0
SNP 0